News
-
DDL 23 concluded on Friday, December 7 with a final plenary talk and podium session, the announcement of contest winners, and news about next year’s DDL meeting. . . . Read more Read more . . .
-
The second day of DDL 23 got underway with an invited talk from OINDP consultant Steve Nichols, who reviewed the state of the inhaled drug market in 2012 with a promise to answer the question,… Read more . . .
-
Meeting chair Gary Pitcairn started off DDL 23 with the announcement of some attendance statistics: just under 500 attendees have registered for this year’s meeting, with 35% of them from pharma companies, 17% from academia,… Read more . . .
-
Aptar Pharma has announced the selection of a customized Landmark dose indicator for Skyepharma’s Flutiform fluticasone propionate/formoterol fumarate MDI. Flutiform is available for the treatment of asthma in Germany, the UK, and several other countries.… Read more . . .
-
The US Patent and Trademark Office has issued Patent number 8,324,266, titled “Compositions, Methods & Systems for Respiratory Delivery of Two or More Active Agents,” to Pearl Therapeutics. The patent covers formulation methods using the… Read more . . .
-
Prosonix has announced that Ken Cunningham will replace Jim Philips as Non-executive Chairman. Cunningham, who is also Chair of the company’s scientific advisory board, is a former CEO of Skyepharma. He has been a member… Read more . . .
-
According to Consort Medical, Nicoventures, a subsidiary of the British American Tobacco Group, has awarded a contract to Consort’s Bespak Division “for the supply of an innovative nicotine inhalation product for use as a safer… Read more . . .
-
Lightlake Therapeutics, which is developing intranasal naloxone to treat eating disorders, has announced the appointment of board member Kevin Pollack as Chief Financial Officer. Pollack joined the board of directors in April 2012. Lightlake Chief… Read more . . .
-
Inhalation and particle engineering specialist Hovione and Swiss chemical development company Solvias have announced an agreement to collaborate on development and manufacturing of co-crystallized drugs. According to Hovione, “This strengthens Hovione’s expertise and experience in… Read more . . .
-
The FDA issued a letter to Alcon dated November 13, 2012 regarding a sales aid that the agency says overstates the efficacy of Alcon’s Patanase olopatadine hydrochloride nasal spray. In the four-page letter, the agency… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland